The integral synaptic vesicle protein SV31 has been shown to bind divalent cations. Here, we demonstrate that SV31 protein synthesized within a cell-free system binds Zn 2+ and to a lower extent Ni 2+ and Cu 2+ ions. Expression with Zn 2+ stabilized the
protein and increased solubility. SV31 was preferentially monomeric in detergent and revealed specific binding of Zn 2+ . When co-translationally inserted into defined nanodisc bilayers, SV31 assembled into dimeric complexes, resulting in increased binding of Zn
2+
. Putative Zn 2+ -binding motifs within SV31 comprise aspartic acid and histidine residues. Sitedirected mutagenesis of two conserved aspartic acid residues leads to a potent decrease in Zn 2+ binding but did not affect dimerization. Synaptic vesicles, abundant pre-synaptic electron-lucent organelles of about 45 nm in diameter, enable neurons to communicate with each other or with neighboring cells via regulated exocytosis of neurotransmitters. Their protein inventory controls all vesicular functions including axonal transport, neurotransmitter uptake, translocation, docking to the pre-synaptic plasma membrane and calcium-triggered fusion as well as their recycling via endocytosis . To date, a considerable variety of synaptic vesicle proteins that regulate these processes in an interacting network have been described . By analyzing the proteome of murine brain-derived synaptic vesicles, we and others identified a large number of proteins which were not previously assigned to the synaptic vesicle compartment (Morciano et al. 2005; Burr e et al. 2006; Takamori et al. 2006; Grønborg et al. 2010) . Among those is a 31 kDa synaptic vesicle protein of 288 amino acids named SV31 or transmembrane protein 163 . Its vesicular localization was confirmed by immunoelectron microscopy of rat and mouse brain synaptosomes . At least one ortholog of mouse SV31 is expressed in other vertebrates. Algorithms of the protein structure predict six transmembrane helices with the N-and C-terminus residing in the cytosol . SV31 shares about 20% amino acid sequence identity with bacterial cobalt-zinccadmium resistance proteins and several transporters of the cation diffusion facilitator family. Initial experiments indicated that SV31 is able to bind Zn 2+ , as well as Cu 2+ and Ni 2+ with lower affinity . Expression of recombinant SV31 in mammalian cells permitted a first analysis of its divalent cation binding properties. However, limited stability and yield of SV31 hampered its further characterization.
To overcome these limitations we employed cell-free (CF) expression for a detailed analysis. In the field of synthetic biology CF expression systems emerge as a potent tool for the production of proteins difficult to express. In particular, integral membrane proteins are suitable targets (Henrich et al. 2015b) as the complexity of expression is largely reduced, toxic effects are minimized and restrictions in targeting and translocation are eliminated. The open accessibility of CF reactions and their high tolerance for numerous additives (Hein et al. 2014 ) allows completely new approaches to synthesize membrane proteins in the presence of detergents [detergent-based cell-free expression (D-CF) mode] or supplied artificial bilayers [lipid-based cell-free expression (L-CF) mode]. In the precipitate forming mode (P-CF) the synthesized membrane proteins precipitate after translation as a result of the lack of hydrophobic environments. The P-CF-generated precipitates form predominantly type I aggregates that can often be solubilized without extensive refolding processes (Junge et al. 2011; Keller et al. 2011) .
This study demonstrates the potential of CF synthetic biology approaches for the functional characterization of a proton-dependent Zn 2+ transporter. We describe the functional characterization of SV31 synthesized in different environments by using the P-CF, D-CF or L-CF mode. CFsynthesized SV31 bound Zn 2+ and with lower affinity Ni 2+ and Cu 2+ . Differences in the oligomeric state of D-CF and L-CF generated SV31 samples were identified by noncovalent mass spectrometry. We present first evidence for the modulation of Zn 2+ binding by SV31 dimerization. Potential Zn 2+ -binding sites of SV31 were identified by site-directed mutagenesis and by chemical amino acid residue modification that abolished Zn 2+ binding. Reconstitution of SV31 into liposomes with encapsulated FluoZin-1 revealed proton-dependent Zn 2+ transport activity that was inhibited after substitution of two aspartic acid residues to alanine.
Materials and methods

DNA manipulations
For substitution of the two identified aspartic acids (D123 and D127) against alanine, the QuickChange II Site-Directed Mutagenesis Kit from Agilent (Waldbronn, Germany) was used. The mutagenic primers were annealed and extended with PfuTurbo DNA polymerase. Primers were as follows: forward, gcc ttc ggg ttt gca ttt gcg gcc atc ctg gcg gtg ctg tcc tcg gcc; reverse, ggc cga gga cag cac cgc cag gat ggc cgc aaa tgc aaa ccc gaa ggc. Restriction-free cloning (van den Ent and L€ owe 2006) was performed to exchange the his-tag in the piVEX2.3~SV31 against the strep-tag. The PCR mixture contained 100 ng/lL template, 25 mM of each nucleoside triphosphate, 19 PfuUltra HF reaction buffer, 100 ng/lL forward and reverse primer and 1 lL PfuUltra HF DNA polymerase (Agilent). The mixture was thermocycled using the following conditions: (i) 2 min initial denaturation at 95°C, (ii) 30 cycles of 30 s denaturation at 95°C and (iii) 10 min final extension at 72°C. Primers were as follows: forward, gag gat ctg aat agc gcc gtc gac tgg agc cac ccg cag ttc gaa aaa tga taa gcg gcc gct aaa tca cta; reverse, tag tga ttt agc ggc cgc tta tca ttt ttc gaa ctg cgg gtg gct cca gtc gac ggc gct att cag atc ctc. The megaprimer PCR method was used to transfer sfGFP into piVEX2.3~SV31. Two PCRs are required and reactions were prepared as follows: 100 ng/lL template, 10 mM each nucleoside triphosphate, 19 Phusion HF buffer, 10 lM forward and reverse primer and 0.5 lL Phusion DNA polymerase. Both mixtures were thermocycled using the following conditions: (i) 30 s initial denaturation at 98°C, (ii) 32 cycles of 10 s denaturation at 98°C and (iii) 10 min final extension at 72°C. Primers for the first PCR were as follows: forward, gac gcg tca tta tga aat gtt tga ggg atc cgg atc cag caa agg aga aga act ttt cac tg; reverse, ctg cgg gtg gct cca gga tcc ttt gta gag ctc atc cat g. For the second PCR 5 lL of the first PCR was used as megaprimers.
To each PCR mixture 1-2 lL Dpn I was added and incubated for 1 h at 37°C to digest the parental DNA. Afterward, the plasmids were transformed in XL1-Blue supercompetent cells (site-directed mutagenesis) or New England Biolabs (Frankfurt, Germany) 5-alpha competent cells (restriction-free cloning, megaprimer method).
Detergents and lipids
Polyethylene glycol P-1,1,3,3-tetramethyl-butylphenyl-ether (Triton X-100) was obtained from Merck Biosciences (Darmstadt, Germany); polyoxyethylene-(23)-lauryl-ether (Brij35), polyoxyethylene-(20)-cetylether (Brij58), polyoxyethylene-(20)-stearyl-ether (Brij78) and digitonin and asolectin PC were obtained from Sigma Aldrich (Taufkirchen, Germany). 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-rac-(1-glycerol) (LMPG), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). N-dodecyl-D-maltoside (DDM) was obtained from AppliChem (Darmstadt, Germany). Dodecyl-phosphocholine (DPC) was purchased from Anatrace (High Wycombe, UK).
Nanodisc preparation
The membrane scaffold protein MSP1E3D1 containing a N-terminal His 6 -tag followed by a Tobacco Etch Virus (TEV) cleavage site (Denisov et al. 2004 ) was expressed and purified as described before (Henrich et al. 2015a) . Before nanodisc (ND) assembly the His 6 -tag was removed from MSP1E3D1 using TEV protease. After overnight TEV cleavage in TEV buffer [50 mM Tris-HCl pH 8.0, 500 lM EDTA, 1 mM dithiothreitol (DTT)] at 22°C, non-cleaved MSP1E3D1 and TEV protease were removed by inverse Ni 2+ purification. The flow through containing cleaved scaffold protein was collected and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). DMPC, DMPG, and DOPC lipids were used for preparing the NDs. Lipids and scaffold protein were mixed in optimized protein-to-lipid ratios (Roos et al. 2012) with 0.1% DPC for 1 h. Disc formation was achieved by detergent removal upon dialysis against 5 l DF-buffer (10 mM TrisHCl pH 8.0, 100 mM NaCl) for 3 days including two buffer exchanges. NDs were concentrated to 0.5-1 mM with Centriprep devices (Merck, Millipore), shock frozen with liquid nitrogen and stored at À80°C.
Liposome preparation
Twenty milligram of asolectin or DMPC was dissolved in 1 mL chloroform and thoroughly dried in a glass vial using a rotary evaporator. Afterward, the lipid film was resuspended in buffer (20 mM Tris, pH 8.2, 100 mM NaCl) and mixed to obtain a homogenous suspension. For fluorescence analysis, the buffer was mixed with 200 lM FluoZin-1 and the buffer was adjusted to a pH of 4.0, 6.0 or 8.0. To support the homogenization process the lipid solution was incubated in a sonication bath. The suspension was extruded with a Mini-Extruder (Avanti Polar Lipids) through a membrane with a 0.2 lm mesh size according to the manufacturer's instructions and liposomes were stored at À80°C. Prior to use, the extrusion procedure was repeated. L-CF reactions containing liposomes with encapsulated FluoZin-1 were protected from light.
Transport of Zn 2+ was analyzed via incubation with 100 lM Zn
2+
for 1 min and monitored with a fluorescence microscope at excitation/emission maxima of 494/516 nm using a Zeiss Axiophot fluorescence microscope (Jena, Germany). Concentration dependence of Zn 2+ transport was measured within a range 5-100 lM and incubation for 15 sec. Quantification of the FluoZin-1 fluorescence intensity was performed with ImageJ 1.43n. K m values were calculated by Michaelis-Menten Fit using the program PRISM.
Cell-free expression technology Self-prepared extracts of E. coli strain A19 were used for CF expression. S30 extract preparation, T7-RNA polymerase preparation and continuous-exchange cell-free expression were performed using the standard protocol as described elsewhere (Schwarz et al. 2007; Reckel et al. 2010; Henrich et al. 2015a) . CF reactions with a volume ratio of reaction mixtures and feeding mixtures of 1 : 15 (analytical-scale reactions) or 1 : 17 (preparative-scale reactions) were incubated for~16 h at 30°C with gentle shaking. Regenerated cellulose membranes with 12-14 kDa cut-off were used for 55 lL analytical-scale reactions. The reactions were incubated in minicontinuous-exchange cell-free expression reactors (Reckel et al. 2010) in 24-well plates (Greiner, Frickenhausen, Germany) holding the feeding mixture. Self-made maxi-continuous-exchange cell-free expression reactors were used for preparative-scale reactions (1-3 mL) and performed with commercial Slide-A-Lyzer units (Thermofisher scientific, Langenselbold, Germany) as reaction mixture container (Reckel et al. 2010) . For the D-CF expression mode, detergents were supplied into the reaction mixture and feeding mixture at the following final concentrations: 0.4% Brij35, 0.4% Brij58, 0.4% Brij78, 0.4% digitonin, 0.1% DDM, or 0.1% Triton X-100. For the L-CF expression mode, pre-formed NDs or extruded liposomes composed out of asolectin or DMPC were added only to the reaction mixture at final concentrations of 20-100 lM and 3 mg/mL, respectively. In reactions containing Zn 2+ ions, the reducing agent DTT was substituted with Tris(2-carboxyethyl) phosphine (TCEP) in identical concentration and EDTA-free Hepes buffer was used. The optimal working range of TCEP and ZnCl 2 was determined in pilot experiments by using superfolder green fluorescent protein (GFP) (sfGFP) expression as monitor.
SV31 protein purification
After incubation, P-CF reactions were centrifuged at 22 000 g for 10 min to pellet the expressed membrane proteins together with coprecipitating impurities. The pellet was washed twice with S30C buffer (10 mM Tris-acetate pH 8.2, 14 mM magnesium acetate, 60 mM potassium acetate and 0.5 mM DTT) and finally suspended in appropriate detergent solutions in a volume equal to the initial reaction mixture volume. The suspensions were incubated at 25°C for 2 h on a shaker to solubilize the membrane proteins. For the solubilization of P-CF-produced SV31, the following detergents dissolved in Milli-Q water were used: 1% (w/v) DPC, 1% (w/v) DDM, or 1% (w/v) LMPG. After incubation, residual precipitate was eliminated by centrifugation at 22 000 g for 10 min and the supernatant was used for further purification. The SV31 protein was affinity purified by employing strep-tactin beads (IBA, G€ ottingen, Germany). Soluble fractions of reaction mixtures or processed P-CF samples were diluted 1 : 3 with strep-buffer (100 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.25 mM TCEP) and loaded on equilibrated strep-resin with a bed volume corresponding to the reaction mixture. Samples were incubated with the resin for 3 h at 22°C or overnight at 4°C. Afterward, beads were washed with 5-column volumes of strep-buffer followed by elution with 3-column volumes of strepelution buffer (100 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.25 mM TCEP, 20 mM desthiobiotin). For the purification of D-CF samples, buffers were supplemented with 0.1% Brij35 or 0.1% Brij78. For mass spectrometry analysis, samples were purified with the strepcolumn and Zn 2+ column and concentrated using Amicon Ultra centrifugal filters (Merck Millipore, Darmstadt, Germany) with 10 kDa cut-off to a final volume of 40 lL.
SDS-PAGE and immunoblotting
For sodium dodecyl sulfate (SDS) gel analysis, protein samples supplemented with 49 SDS sample buffer containing 250 mM TrisHCl pH 6.8, 8% SDS, 40% glycerol and 0.04% bromophenol blue were separated on 15% (w/v) Tris glycine-SDS gels or 11% Tris tricine-SDS gels and stained with a colloidal Coomassie Brilliant Blue (CBB) solution (0.02% CBB G250, 5% aluminum phosphate, 10% ethanol, 2% orthophosphoric acid). For western blot analysis, the gels were transferred on a 0.45 lm polyvinylidene difluoride membrane (GE Healthcare, M€ unchen, Germany) in a semi-dry western blot apparatus for 55 min at 150 mA. Membranes were blocked for 1 h at 22°C in blocking buffer consisting of phosphatebuffered saline supplemented with Tween (PBST) (123 mM NaCl, 7.4 mM Na 2 HPO 4 , 4.3 mM KH 2 PO 4 , 0.1% Tween20) and additional 5% skim milk powder (AppliChem). The membrane was incubated overnight with the primary rabbit anti-SV31 antibody (Synaptic Systems, G€ ottingen, Germany) at 1 : 1000 dilution at 4°C. The membrane was washed five times at 22°C with 20 mL of blocking buffer. The membrane was subsequently incubated for 1 h at 22°C with the secondary antibody anti-rabbit IgG horseradish peroxidase conjugate (Sigma Aldrich, Taufkirchen, Germany) at a 1 : 4000 dilution in PBST buffer. The membrane was subsequently washed five times at 22°C with PBST buffer. Finally, the blots were analyzed by chemiluminescence in an enhanced chemiluminescence machine (Image QuantTM LAS 4000 of GE Healthcare). Immunosignals presented were obtained from one gel if not otherwise indicated. Pixels of immunodetected bands were quantified using ImageJ software (version 1.43n) (National Institute of Mental Health, Bethesda, Maryland, USA).
Immobilized metal ion affinity chromatography
Immobilized metal ion affinity chromatography was performed using chelating Sepharose fast-flow assay (GE Healthcare) to determine the divalent cation binding capacity of the in vitro translated SV31. Two milliliters of chelating Sepharose was packed onto a column. After initial washing steps using distilled water, the column was loaded with 1 mL of the desired 0.2 M metal ion solution. To remove excessive metal ions, the column was washed with 10 mL of distilled water. The column was then equilibrated by washing with binding buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.25 mM TCEP). Crude reaction mixtures containing recombinant SV31 or purified SV31 samples diluted in 1 mL of binding buffer were loaded onto the column. The column was washed with 10 mL binding buffer. One milliliter fractions of the flow through (F) were collected. For elution, binding buffer was adjusted to pH 3.0 by HCl or binding buffer with 5-100 mM imidazole was used. Fractions F and eluted material (E) were collected and subsequently immunoblotted using the anti-SV31 antibody (1 : 1000).
GFP fluorescence analysis GFP fluorescence was measured as described before (Schwarz et al. 2010; Roos et al. 2012) . After expression, the supernatant and the pellet fraction of the reaction were centrifuged for 10 min at 18 000 g and the samples were stored on ice for 1 h. The pellets were resuspended in buffer (10 mM Tris-acetate, pH 8.2, 14 mM Mg (OAc) 2 , 60 mM KOAc) with the same volume as the reaction mixture. Three microliter of the supernatant or the resuspended pellet fractions were mixed with 297 lL of assay buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl) in black 96-well microtiter plates (96F Nunclon Delta Black Microwell SI, ON 137101, Nunc, Langenselbold, Germany). Fluorescence measurements were performed using a TECAN Magellan plate reader (Tecan, Mannedorf/ Z€ urich, Switzerland). Samples were excited at 485 nm and emission was recorded 10 times per well at 510 nm. The concentration of GFP in the soluble fraction was calculated according to a calibration curve (Schwarz et al. 2010; Roos et al. 2012) .
LILBID mass spectrometry For laser-induced liquid bead ion desorption-mass spectrometry (LILBID-MS) analysis, the buffer for SV31 in nanodiscs was changed to 50 mM ammonium acetate, pH 6.8, in desalting columns (Zeba Micro Spin Desalting Columns, article number 89887, Thermofisher Scientific, Langenselbold, Germany) with a 7 kDa cut-off filter directly before the measurement. The columns were first equilibrated by four runs with exchange buffer for 1 min at 200 g. SV31 samples were exchanged for 2 min at 200 g. For SV31 sample in detergent, 0.1% Brij35 was added to the exchange buffer. Three microliter samples were used for each measurement. In LILBID-MS, 30 lm droplets are generated by a commercially available piezo-driven droplet generator MD-K-130 from Microdrop Technologies GmbH, Norderstedt, Germany, operating with a frequency of 10 Hz. The droplets are transferred to vacuum and irradiated by an IR laser at 2.94 lm, a vibrational absorption wavelength of water, which leads to the explosive expansion of the sample droplet. The released ions are accelerated by a pulsed electric field and the mass of the ions is analyzed by a homebuilt reflectron time-of-flight setup. The LILBID-MS instrument was operated at standard settings (Morgner et al. 2006) . The presented spectra show the averaged signals of 2500 droplets. Data processing and signal assignment were done using the software Massign (Morgner and Robinson 2012) .
In vivo and in vitro quantification of the Zn 2+ binding of mutated
SV31
The experimental protocol of cell transfection and Zn 2+ -binding assay was performed as described elsewhere . In brief, for transient transfection of PC12 cells, the plasmid pDsRed~SV31-RFP was employed. The aspartic acids D123 and D127 in the primary structure of SV31 were substituted to alanine residues. After transient transfection of nerve growth factor (NGF)-differentiated PC12 cells with these constructs, cells were incubated for 5 min with 5 lM of the cell-permeant Zn 2+ indicator FluoZin-3.
Fluorescence was monitored at excitation/emission maxima of 494/ 516 nm using a Zeiss Axiophot fluorescence microscope (Jena, Germany). For surface plotting of FluoZin-3 fluorescence and pixel quantification of fluorescent areas, ImageJ software (version 1.43n) was used. Pixel intensity was measured using grayscale with 256 levels of gray and background fluorescence of the surrounding medium was subtracted. For in vitro analysis, SV31 was expressed with NDs (DMPC) and purified by immobilized metal ion chromatography. The flow through, washes, and elution fractions were analyzed by SDS-PAGE and western blotting. The pixel intensity was quantified using ImageJ software (version 1.43n).
Furthermore, SV31 expressed with NDs (DMPC) was mixed with 10 mM diethyl pyrocarbonate (DEPC) that selectively modifies the histidine residues and incubated for 30 min, 1 h, and 1.5 h, respectively. After incubation, the reactions were terminated by adding 20 mM imidazole to quench unreacted DEPC. The protein was then loaded onto a Zn 2+ Sepharose column, and flow through and eluate fractions were collected.
Statistics
Statistical analysis was performed with Microsoft Excel 2010. The data are presented as means AE standard deviation. For comparison of two independent groups, unpaired Student's t-tests were used. Statistically significant differences are indicated in the Figures by **p < 0.01 and ***p < 0.001.
Results
P-CF expression of SV31 and Zn 2+ -binding analysis
An attached C-terminal strep-tag was employed for purification of SV31 and its purified plasmid DNA was added as a template into the reaction mixture. SV31 was first produced in the P-CF mode without detergents. The concentration of Mg 2+ ions is critical for the preparative-scale CF production of proteins and the expression of SV31 was monitored within a range 12-22 mM. Immunodetection of expressed SV31 revealed a Mg 2+ optimum of 20 mM (Fig. 1a) . Further in vitro biophysical and functional analysis of CF-expressed SV31 required its solubilization in detergent micelles. A variety of detergents were screened for their efficiencies to solubilize P-CF-produced SV31. Solubilization efficiency was analyzed in 1% (w/v) LMPG, 1% (w/v) DPC, and 1% (w/ v) DDM. Solubilization of SV31 was apparently 90% efficient in LMPG, 80% in DPC, and 60% in DDM (Fig. 1b and c) . Ion binding of the different P-CF samples was monitored with the chelating Sepharose fast-flow Zn 2+ -binding assay and flow through and eluate fractions were analyzed by immunodetection using anti-SV31 antibody. Zn 2+ -bound SV31 was eluted with a pH shift to 3.0 (Fig. 1d) . Binding to Zn 2+ was strongest after solubilization of SV31 in DPC.
D-CF production of SV31
As an alternative option that prevents the initial precipitation of SV31 after translation, the proteins were synthesized in the D-CF mode in the presence of 0.4% (w/v) Brij35, 0.4% (w/v) Brij58, 0.4% (w/v) Brij78, 0.1% (w/v) DDM, 0.4% (w/v) digitonin, or 0.1% (w/v) Triton X-100 ( Fig. 2a and b) .
Subsequently, the SV31-containing proteomicelles consisting of Brij35 or Brij78 were purified by strep-tactincoated beads to apparent purity (Fig. 2c) . The detergents Brij35 and Brij78 revealing a high solubilization efficacy were chosen for the analysis of the Zn 2+ -binding capacity of D-CF-expressed SV31 (Fig. 2d) . SV31 was applied to a Zn 2+ -loaded Sepharose column and the flow through, wash, and eluate fractions of increasing imidazole concentrations (10-100 mM) were collected. The majority of SV31 solubilized in either Brij35 or Brij78 eluted at 10 mM imidazole. Similarly, SV31 first purified via strep-tag and then Zn 2+ column bound eluted at the same imidazole concentration (Fig. 2d) .
To evaluate a potential impact of Zn 2+ on SV31 expression, the reducing agent DTT in the reaction mixture has to be replaced as a result of the formation of insoluble aggregates together with Zn 2+ . For DTT substitution the reducing agent TCEP was chosen and the compatibility with the CF system was first monitored by the expression of sfGFP (Fig. 3a, left) . Expression was saturated at 2 mM TCEP corresponding to the effect of 2 mM DTT. Similarly, the compatibility of the CF expression system with the addition of Zn 2+ ions was analyzed and the system tolerated the addition of Zn 2+ up to a concentration of 100 lM without substantial loss in expression yield (Fig. 3a, right) . The presence of Zn 2+ had a stabilizing effect on SV31 (Fig. 3b-d ) as we observed a positive effect on the solubilization in the presence of Brij35 (Fig. 3b) , Brij78 (Fig. 3c) or DDM (Fig. 3d) . Optimal solubilization of at least 80% was achieved at approximately 50 lM Zn 2+ (Brij35, Brij78) or 100 lM Zn 2+ (DDM), respectively (Fig. 3) . expression in the P-CF mode. Recombinant SV31 was detected using the polyclonal SV31 antibody. (b and c) Solubilization efficiency of SV31 produced in the P-CF mode. P-CF-generated precipitates were suspended in 1% 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-rac-(1-glycerol) (LMPG), 1% dodecyl phosphocholine (DPC), or 1% (w/v) ndodecyl-D-maltoside (DDM) and solubilized fractions (S) were separated from the residual precipitate (P) by centrifugation. Percentage of solubilization efficacy was determined using pixel intensity of the immunosignals. (d) Zn
2+
-binding capacity of SV31 solubilized in the three different detergents. Solubilized precipitates obtained by P-CF expression mode were subjected to the chelating Sepharose fast-flow assay. Flow through (F) and eluate (E) fractions eluted with a pH shift to 3.0 were immunodetected using anti-SV31 antibodies.
Reconstitution and Zn
2+ -binding activity of SV31 in nanodiscs As lipid bilayers are the natural environment of membrane, proteins and lipids often play important roles in maintaining membrane protein structure, function, and stability, SV31 was expressed in the L-CF mode in the presence of NDs. NDs are soluble nanoscale phospholipid bilayers encircled by amphipathic membrane scaffold proteins, which can self-assemble with integral membrane proteins (Bayburt and Sligar 2010) and have proven to be versatile tools for the study of many types of membrane proteins (Denisov and Sligar 2016) . The L-CF approach in the presence of pre-formed NDs is an ideal strategy for screening for lipid preferences and lipid dependency of membrane proteins (Henrich et al. 2016) . Solubilization efficacy of SV31 expressed in NDs assembled with different lipids (DMPC, DMPG, DOPC) was highest with DOPC ( Fig. 4a) . Interestingly, phosphatidylcholine is the major membrane-forming phospholipid in eukaryotes (van Meer et al. 2008 ). This method yields approximately 8 lM of soluble recombinant SV31 in the reaction mixture. NDs containing SV31 were further purified by strep-tactin beads and subsequently analyzed for binding to a Zn 2+ -loaded Sepharose column (Fig. 4b) .
Interestingly, the Zn 2+ -binding capacity of SV31 is increased in lipid environments if compared with detergents, as demonstrated by the retarded elution upon pH 3.0 treatment (Fig. 4c, upper graph) as well as by the higher elution concentration of imidazole (60 mM instead of 10 mM, Fig. 4c , lower graph) from a Zn 2+ -loaded column. SV31 reconstituted in NDs was further analyzed for its ability to bind Mn 2+ , Cu 2+ , and Ni 2+ (Fig. 4d) . SV31 does not bind Mn 2+ , and the binding of Cu 2+ and Ni 2+ was weaker than that of Zn 2+ . SV31 bound to a Cu 2+ -or Ni 2+ -loaded column eluted at 10 mM or 20-40 mM imidazole, respectively (Fig. 4d) . We next tested the impact of the lipid environment on SV31 stability. SV31 was expressed either in the D-CF mode with Brij35 or in the L-CF mode with NDs/DMPC and the samples were purified with strep-tactin beads. After storage for 1 week at 4°C, SV31 reconstituted in NDs/DMPC showed still strong binding to Zn 2+ ions, whereas the Zn 2+ binding of SV31 in Brij35 was almost completely abolished and most of the protein was present in the flow through fraction (Fig. 4e and f) . These results indicate that the lipid environment is essential for the robust stability of SV31.
SV31 reconstituted in lipid bilayers assembles into a dimer
As protein folding and stability is often linked to its oligomeric state, we analyzed SV31 solubilized either in the detergent Brij35 or in NDs/DMPG by non-covalent mass spectrometry. Only SV31 dimers in various combinations with the scaffold protein were detected in the SV31-ND/ DMPG sample (Fig. 5, upper graph) . This indicates that in the context of DMPG membranes a stable dimeric complex of SV31 is formed. In contrast, mainly SV31 monomers in combination with dimers were observed in the Brij35 proteomicelles (Fig. 5, lower graph) . The detergent environment appears therefore less suitable for stabilizing SV31 dimers. The preference of SV31 monomers could contribute to the observed lower Zn 2+ affinity of the D-CF samples.
Identification of Zn 2+ -binding sites
Comparison of the amino acid sequence of SV31 with the vesicular Zn 2+ transporter ZnT3 from Mus musculus, of the bacterial Zn 2+ transporter YiiP (E. coli), and of the bacterial cobalt-zinc-cadmium resistance protein (Ralstonia metallidurans) reveals matches in conserved and homologous amino acids . Of note, SV31 contains two aspartic acid residues D123 and D127 in the transmembrane helix TM2 which match to D45 and D49 involved in Zn The two aspartic acid residues D123 and D127 potentially involved in Zn 2+ binding were substituted to alanine residues in the vector constructs piVEX2.3~SV31 (for in vitro analysis, Fig. 6a ) and pDsRed~SV31-RFP (for in vivo analysis in transfected PC12 cells) by site-directed mutagenesis. The mutated construct SV31-S3 still forms a stable dimeric SV31 complex comparable to wild-type SV31 in the context of DMPG membranes (Fig. 6b) .
The mutated SV31-S3 construct was analyzed in vitro after L-CF expression in NDs/DMPC employing the chelating Sepharose assay. Zn 2+ binding of the mutant was reduced to about 50% if compared with the SV31 wild type (Fig. 6c, left) . To investigate the impact of the histidines (H25, H78, H145, H174, H244, and H283) on the Zn 2+ -binding capacity of SV31, wild-type SV31 and double-mutated SV31-S3 were first incubated with DEPC for 30, 60, and 90 min, which selectively modifies histidine residues, and their Zn 2+ -binding activity was determined (Fig. 6c, middle) . Incubation with DEPC abolished the residual Zn 2+ -binding activity of mutated SV31-S3 in a time-dependent manner, whereas it remained at 50% in wildtype SV31. In vivo analysis was performed in a complementary approach by recombinant expression of mutated SV31-S3 in NGF-differentiated PC12 cells (Fig. 6c, right) and compared with the wild type for quantitative analysis of their Zn 2+ -binding capacities. Zn 2+ binding was significantly reduced in the mutated version of SV31 also in vivo. Thus, the two conserved aspartic acids together with yet unidentified histidine residues are involved in the Zn 2+ -binding activity of SV31. 
Zn 2+ transport activity of SV31 expressed in liposomes
The planar membranes of NDs that are accessible from both sides are not suitable for the analysis of transport activity as they do not feature compartmentalization. We therefore monitored the co-translational reconstitution of synthesized SV31 into pre-formed asolectin or DMPC liposomes that have been added to the CF reaction mixtures. Western blot analysis of both, crude (Fig. 7a) and Zn 2+ column-purified SV31 containing proteoliposomes (Fig. 7b) , indicated successful incorporation of the protein into bilayers composed out of either lipid at equal efficacy. Furthermore, we could show that SV31 is able to transport Zn 2+ . Proteoliposomes -binding capacity in Brij35 (dark blue and light blue) and NDs (DMPC) (green and dark green) before and after 1 week at 4°C. F, flow through; W, wash; E, eluate.
acidified to pH 6.0 exhibit a clear accumulation of luminal fluorescence after addition of 100 lM Zn 2+ (Fig. 7c , upper panel, arrows in inset), whereas SV31 proteoliposomes with an interior pH of 8.0 reveal no accumulation of FluoZin-1 fluorescence exceeding the background fluorescence (Fig. 7c, lower panel) . Quantification of Zn 2+ transport verifies highly significant transport activity at pH 6.0 (Fig. 7d ) as compared to fluorescence at pH 8.0 or in the absence of Zn 2+ (Fig. 7d) . Liposomes acidified to either pH 6.0 or pH 8.0 in the absence of SV31 served as negative control (Fig. 7e) . Further acidification of proteoliposomes to pH 4.0 resulted in instability of liposomes (not shown). Zn 2+ transport strictly depends on external Zn 2+ concentrations. The K m value of proton-dependent Zn 2+ transport at pH 6.0 was 44.33 AE 12.23 lM (Fig. 7f ). These results demonstrate that SV31 actively transports Zn 2+ in a proton-dependent manner.
Interestingly, Zn 2+ transport was completely abolished in the SV31 mutant lacking the two aspartic acid residues D123 and D127 (Fig 7g and h) . This indicates that despite some residual binding of Zn 2+ , the mutated SV31-S3 is nonfunctional in Zn 2+ transport (Fig. 7h) .
Discussion
The functional role of zinc in the diverse subcompartments of the nervous system requires locally precisely balanced concentration levels. Zn 2+ occurs in the cytosol in the picomolar range. However, in the proximity of nerve terminals it reaches micromolar and inside synaptic vesicles even millimolar concentrations (Colvin et al. 2006) . Zn 2+ affects multiple receptor types including glutamatergic, serotonergic, and especially glycine receptors (Park et al. 2008; Cichy et al. 2009 ). In addition, a metabotropic Zn 2+ -sensing receptor has been described (Besser et al. 2009 ). In recent years Zn 2+ came into the focus of medical research because of its relevance for neurodegenerative disorders such as Alzheimer's and Parkinson's disease (Brewer et al. 2010) . Because of the importance of Zn 2+ in the nervous system, we analyzed in detail the structure and function of the vesicular Zn 2+ -binding protein SV31.
One ortholog of mouse SV31 is exclusively expressed in neurons of vertebrate brains. We previously reported that the protein structure of SV31 reveals four primary and two secondary helices classified as hydrophobic or partially hydrophilic transmembrane segments, respectively, spanning the vesicular membrane with the N-and C-termini exposed to the cytosol . The primary structure exhibited similarities to members of the ubiquitous cation diffusion facilitator protein family involved in divalent cation transport in bacteria, archaea, and eukaryotes (Paulsen and Saier 1997; . Assays employing metal ion columns demonstrated that SV31 is capable of binding divalent cations. 2+ . In this report we first aimed to decipher the structural requirements of SV31 for metal binding by CF reconstitution and to evaluate its putative function as a transporter. Numerous prerequisites have to be fulfilled for this approach. Yield, sample purity, and robust stability of SV31 need to be optimized. Functional SV31 as judged by its Zn 2+ -binding capacity can be obtained by P-CF expression and subsequent solubilization in DPC, by D-CF expression in the presence of the detergent Brij35, or by L-CF expression reconstituted into NDs. In all expression modes, SV31 can be subsequently purified by affinity chromatography with strep-tactin beads. Interestingly, the presence of micromolar Zn 2+ has already a positive effect on SV31 solubility during expression. Zn 2+ ions had also a stabilizing effect on CF-expressed soluble Zn 2+ -binding proteins (Matsuda et al. 2006) and for the crystallization of ion channels (Takeshita et al. 2014) .
The selective binding of Zn 2+ , Ni 2+ , or Cu 2+ could be confirmed with CF-synthesized SV31-ND complexes. In addition, stability analysis revealed that SV31-ND/DMPC complexes are long-time stable as a result of the phospholipid bilayer environment that closely mimics the anisotropic physical and chemical properties of biological membranes (Nath et al. 2007) . In contrast, stability of SV31 in detergents was clearly reduced. A key advantage of the implemented L-CF strategy is therefore its essentially detergent-free production pathway of SV31 (Ritchie et al. 2009; Roos et al. 2014) .
LILBID-MS analysis demonstrated that functionally reconstituted SV31 assembled into a dimer within membranes composed of DMPG and potentially also other lipids. This is in accordance with the Zn 2+ transporter YiiP that also operates as a dimer (Lu and Fu 2007) . Overall, six transmembrane domains and homodimerization are considered to be main characteristics of the cation diffusion facilitator protein family (Weijers 2010) . Interestingly, the -binding capacity of both SV31 derivatives was further reduced in a time-dependent manner upon treatment with the histidine residues modifying agent diethyl pyrocarbonate (DEPC). The SV31 proteins were incubated with 10 mM DEPC for 30 min, 60 min, or 90 min, and Zn 2+ binding was monitored with a Zn 2+ column (C, middle graph). The in vivo Zn 2+ -binding capacity in transfected PC12 cells-expressing double-mutated SV31-S3 as compared to wild type (wt) was also reduced but to a lower extent (right graph). Unpaired student's t-test **p < 0.01, ***p < 0.001. (Lu and Fu 2007) . For YiiP each homodimer contains six Zn 2+ -binding sites (Lu et al. 2009 ). In this context it is noteworthy that mutation of the two aspartic acid residues D123 and D127 to alanine does not interfere with homodimer assembly of SV31 in nanodiscs, but lacks any Zn 2+ transport activity. It has been reported that cellular zinc levels are modulated by the interaction of SV31 with the vesicular transient receptor potential cation channel Mucolipin-1. When cells are acutely exposed to 100 lM exogenous Zn 2+ , SV31 regulates the intracellular Zn 2+ distribution in the cytoplasm and in vesicular compartments in a concerted action with the vesicular transient receptor potential cation channel Mucolipin-1 (Cuajungco et al. 2014) . To evaluate a proposed Zn 2+ transport activity of SV31, we reconstituted SV31 in liposomes and subsequently purified the proteoliposomes with a Zn 2+ -loaded Sepharose column. SV31 proteoliposomes containing the membrane impermeable Zn 2+ chelator
FluoZin-1 showed accumulation of green fluorescence inside liposomes when they were acidified to a pH of 6.0, suggesting that SV31 functions as a proton-Zn 2+ antiporter. There is still a general scarcity of kinetic data for zinc transporters and zinc-binding kinetics (Blindauer 2015) . Thus, comparison is limited. The K m determined for SV31 is in the range of values reported for the bacterial Zn
2+
transporter ZitB of about 100 lM (Chao and Fu 2004) . Such relatively high K m values are physiological relevant as even local millimolar concentrations of Zn 2+ are reached inside synaptic vesicles (Colvin et al. 2006) .
SV31 shares approximately 20% sequence homology and structural similarity with murine ZnT3, a vesicular Zn 2+ transporter with eight mammalian paralogs (Kambe 2012) . Whereas mouse ZnT3 is expressed in several organs (Palmiter et al. 1996; Smidt and Rungby 2012) , mouse SV31 is exclusively expressed in brain . Neither the location of ZnT3 protein nor mRNA in the brain coincides with the distribution of SV31 . SV31 is mainly localized in the molecular layer of the cerebellum, the external plexiform layer of the olfactory bulb, layer 1 of the piriform and periamygdaloid cortex, the habenula, and the adjacent dorsal lateral thalamic nucleus ). SV31 co-localizes with both the vesicular transporters vGluT1 and vGAT . Interestingly, ZnT3 knockdown has been linked to neurodegenerative diseases such as Alzheimer's disease and depression (Beyer et al. 2009; Rafalo et al. 2016 ) and owing to the close homology in amino acid sequence and function a potential role of dysfunctional SV31 within these diseases could be hypothesized.
In summary, we performed for the first time functional in vitro studies of SV31 at the molecular level and our results imply that it functions as a proton Zn 2+ antiporter. Optimized CF expression protocols allowed the production of highquality SV31 samples in different environments. We demonstrate the binding and the proton-dependent transport of Zn 2+ by SV31 and we have identified amino acid residues important for its binding and transport activity. Moreover, we demonstrate that SV31 forms stable dimers in lipid environments and we present evidence that dimerization has a strong impact on Zn 2+ binding. Our protocols will provide a solid basis for further structural and functional studies on SV31 and other related synaptic vesicle transporters. The distinct synaptic localization of SV31 may attribute specific and yet undiscovered functions to subsets of synapses.
